{"id":24933,"date":"2022-10-12T10:48:50","date_gmt":"2022-10-12T08:48:50","guid":{"rendered":"https:\/\/www.maiwald.eu\/?post_type=presseberichte&p=24933"},"modified":"2022-11-02T10:52:09","modified_gmt":"2022-11-02T09:52:09","slug":"royalty-pharma-announces-rd-funding-collaboration-with-merck","status":"publish","type":"presseberichte","link":"https:\/\/www.maiwald.eu\/en\/press-coverage\/royalty-pharma-announces-rd-funding-collaboration-with-merck\/","title":{"rendered":"Royalty Pharma announces R&D Funding Collaboration with Merck"},"content":{"rendered":"\n

Novel collaboration structure supports pipeline innovation<\/strong><\/h3>\n\n\n\n

NEW YORK, NY, October 12, 2022 <\/strong>– Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being evaluated in a Phase 2b study for the treatment of schizophrenia.<\/p>\n\n\n\n

\u201cWe are excited to collaborate with Merck,\u201d said Pablo Legorreta, Royalty Pharma\u2019s founder and Chief Executive Officer. \u201cThis creative agreement is a great example of how Royalty Pharma provides innovative, win-win funding solutions and supports exciting medicines like MK-8189 across the biopharma industry. Royalty Pharma sees an exciting future opportunity to partner with Merck and other global pharmaceutical companies on drug development.\u201d<\/p>\n\n\n\n

Under the agreement Royalty Pharma will provide $50 million upfront to Merck to support ongoing development of MK-8189. Following Merck\u2019s decision to proceed with Phase 3, Royalty Pharma has the option to provide an additional $375 million to co-fund the pivotal clinical development program. Royalty Pharma will be eligible for milestone payments associated with certain regulatory approvals for MK-8189 as well as royalties on annual worldwide sales of any approved product.<\/p>\n\n\n\n

\u201cThere remains a serious unmet need for new therapeutic options for patients with schizophrenia,\u201d said Dr. Michael Egan, vice president, Neuroscience, Global Clinical Development, Merck Research Laboratories. \u201cWe look forward to progressing the development of MK-8189 by means of this creative agreement with Royalty Pharma.\u201d<\/p>\n\n\n\n

Royalty Pharma is a leader in collaborating with biopharmaceutical companies to jointly fund late-stage development programs. The combination of scale and a long-term outlook across the clinical, regulatory and commercial phases of a product\u2019s lifecycle positions Royalty Pharma as a unique partner for the industry.<\/p>\n\n\n\n

For more information about the ongoing Phase 2b clinical trial of MK-8189 please visit clinicaltrials.gov<\/a>.<\/p>\n\n\n\n

Advisors<\/strong><\/h3>\n\n\n\n

Goodwin Procter, Fenwick & West and Maiwald<\/a> acted as legal advisors to Royalty Pharma.<\/p>\n\n\n\n

(\u2026)<\/p>\n\n\n\n

This text is a press release from Royalty Pharma. The full text version of the article can be found here<\/a>.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-24933","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/24933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":5,"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/24933\/revisions"}],"predecessor-version":[{"id":24942,"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/24933\/revisions\/24942"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/media?parent=24933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}